Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| STANDARD BIOTOOLS INC.LAB · Entity 6116 | SVP & Chief Business Officer | August 20, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
STANDARD BIOTOOLS INC.
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,480,823 |
Reported balance
After 2026-08-20 transaction · row 1
1 source rowRow 1 · 2026-08-20 · Tax withholding · Disposed 25,729 · Balance 1,480,823 F1: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units ("RSUs") granted to the reporting person on May 20, 2024, March 21, 2025 and March 20, 2026, which grants were originally reported on Form 3 and Form 4s filed with the U.S. Securities and Exchange Commission on September 3, 2024, March 24, 2025 and April 8, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units ("RSUs") granted to the reporting person on May 20, 2024, March 21, 2025 and March 20, 2026, which grants were originally reported on Form 3 and Form 4s filed with the U.S. Securities and Exchange Commission on September 3, 2024, March 24, 2025 and April 8, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IsoPlexis Corp
Report date March 21, 2023 · Filed March 21, 2023
Section 16 reporting ended · disclosed 2023-03-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 1
1 source rowRow 1 · 2023-03-21 · Disposition to issuer · Disposed 914,366 · Balance 0 F1: On March 21, 2023, pursuant to the Agreement and Plan of Merger, dated as of December 21, 2022 (the Merger Agreement), by and among IsoPlexis Corporation, a Delaware corporation (IsoPlexis), Berkeley Lights, Inc., a Delaware corporation (Berkeley Lights), and Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Berkeley Lights, each share of common stock, par value $0.001, of IsoPlexis (IsoPlexis Common Stock) reported in this Form 4 was converted into the right to receive 0.6120 fully paid and nonassessable shares of common stock, par value $0.00005, of Berkeley Lights (Berkeley Lights Common Stock), together with cash in lieu of fractional shares of Berkeley Lights Common Stock, if any, and any unpaid dividends or other distributions. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2025-10-31 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-21 · Disposition to issuer · Disposed 834 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F3: Vested 25% on August 31, 2019 and thereafter in 36 equal monthly installments. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2025-10-31 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-21 · Disposition to issuer · Disposed 19,000 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F4: Vested 25% on May 25, 2017 and thereafter in 36 equal monthly installments. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.44 · Expires 2026-10-19 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-21 · Disposition to issuer · Disposed 52,000 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F5: Vested 25% on October 20, 2017 and thereafter in 36 equal monthly installments. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2027-10-04 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-21 · Disposition to issuer · Disposed 14,000 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F6: Vested 25% on December 26, 2019 upon achievement of performance target and thereafter in 36 equal monthly installments. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2027-10-04 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-21 · Disposition to issuer · Disposed 14,000 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F7: Vests 25% one year after achievement of sale target and thereafter in 36 equal monthly installments. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2027-10-04 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-03-21 · Disposition to issuer · Disposed 112,000 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F8: Vested 25% on October 5, 2018 and thereafter in 36 equal monthly installments. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2028-01-15 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-03-21 · Disposition to issuer · Disposed 24,000 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F9: Vested 25% on January 16, 2019 and thereafter in 36 equal monthly installments. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2028-02-11 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-03-21 · Disposition to issuer · Disposed 48,000 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F10: Vested 25% on August 1, 2018 and thereafter in 36 equal monthly installments. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2028-06-28 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-03-21 · Disposition to issuer · Disposed 52,000 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F11: Vested 25% on June 29, 2019 and thereafter in 36 equal monthly installments. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2028-09-26 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-03-21 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F12: Vested 25% on September 27, 2019 and thereafter in 36 equal monthly installments. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2028-12-13 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-03-21 · Disposition to issuer · Disposed 96,000 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F13: Vested 25% on December 5, 2019 and thereafter in 36 equal monthly installments. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2030-04-18 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-03-21 · Disposition to issuer · Disposed 680,000 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F14: Vested in full as of December 15, 2020. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.81 · Expires 2031-06-07 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2023-03-21 · Disposition to issuer · Disposed 744,000 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F15: Vested 25% on June 8, 2020 and thereafter in 36 equal monthly installments. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.43 · Expires 2032-03-31 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2023-03-21 · Disposition to issuer · Disposed 296,100 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F16: Vests 25% on March 31, 2023 and thereafter in 36 equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 21, 2023, pursuant to the Agreement and Plan of Merger, dated as of December 21, 2022 (the Merger Agreement), by and among IsoPlexis Corporation, a Delaware corporation (IsoPlexis), Berkeley Lights, Inc., a Delaware corporation (Berkeley Lights), and Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Berkeley Lights, each share of common stock, par value $0.001, of IsoPlexis (IsoPlexis Common Stock) reported in this Form 4 was converted into the right to receive 0.6120 fully paid and nonassessable shares of common stock, par value $0.00005, of Berkeley Lights (Berkeley Lights Common Stock), together with cash in lieu of fractional shares of Berkeley Lights Common Stock, if any, and any unpaid dividends or other distributions.
F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions.
F3: Vested 25% on August 31, 2019 and thereafter in 36 equal monthly installments.
F4: Vested 25% on May 25, 2017 and thereafter in 36 equal monthly installments.
F5: Vested 25% on October 20, 2017 and thereafter in 36 equal monthly installments.
F6: Vested 25% on December 26, 2019 upon achievement of performance target and thereafter in 36 equal monthly installments.
F7: Vests 25% one year after achievement of sale target and thereafter in 36 equal monthly installments.
F8: Vested 25% on October 5, 2018 and thereafter in 36 equal monthly installments.
F9: Vested 25% on January 16, 2019 and thereafter in 36 equal monthly installments.
F10: Vested 25% on August 1, 2018 and thereafter in 36 equal monthly installments.
F11: Vested 25% on June 29, 2019 and thereafter in 36 equal monthly installments.
F12: Vested 25% on September 27, 2019 and thereafter in 36 equal monthly installments.
F13: Vested 25% on December 5, 2019 and thereafter in 36 equal monthly installments.
F14: Vested in full as of December 15, 2020.
F15: Vested 25% on June 8, 2020 and thereafter in 36 equal monthly installments.
F16: Vests 25% on March 31, 2023 and thereafter in 36 equal monthly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2026 Filed Aug 24, 2026 21:06 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 25,729 | $0.67 | $17,289.89 |
DisclosureSEC source: 0001193125-26-363767 · ownership.xml · nonDerivative · entry 1 Mackay Sean · CIK 0001875501 · SVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,480,823 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units ("RSUs") granted to the reporting person on May 20, 2024, March 21, 2025 and March 20, 2026, which grants were originally reported on Form 3 and Form 4s filed with the U.S. Securities and Exchange Commission on September 3, 2024, March 24, 2025 and April 8, 2026. Read SEC document |
| June 20, 2026 Filed Jun 23, 2026 21:45 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-279833 · ownership.xml · nonDerivative · entry 1 Mackay Sean · CIK 0001875501 · SVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,506,552 F1 · shares: Represents restricted stock units ("RSUs"), 40% of which will vest on June 20, 2027, and the remaining 60% of which will vest on June 20, 2028 subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Each RSU represents the right to receive one share of common stock upon vesting. Read SEC document |
| May 20, 2026 Filed May 22, 2026 21:17 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 25,729 | $1.00 | $25,729.00 |
DisclosureSEC source: 0001193125-26-237182 · ownership.xml · nonDerivative · entry 1 Mackay Sean · CIK 0001875501 · SVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,006,552 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024, March 21, 2025 and March 20, 2026, which grants were originally reported on Form 3 and Form 4s filed with the U.S. Securities and Exchange Commission on September 3, 2024, March 24, 2025 and April 8, 2026, respectively. Read SEC document |
| March 20, 2026 Filed Apr 9, 2026 01:55 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to buy) · Derivative | 612,240 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001193125-26-148614 · ownership.xml · derivative · entry 2 Mackay Sean · CIK 0001875501 · SVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 612,240 Underlying: Common Stock · 612,240 shares Expires 2036-03-20 F2 · derivative.exercise_date: The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2026, with the remaining shares vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| March 20, 2026 Filed Apr 9, 2026 01:55 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 272,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-148614 · ownership.xml · nonDerivative · entry 1 Mackay Sean · CIK 0001875501 · SVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,032,281 F1 · shares: Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2026 and the remaining RSUs vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 22:44 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 19,661 | $1.15 | $22,610.15 |
DisclosureSEC source: 0001193125-26-067638 · ownership.xml · nonDerivative · entry 1 Mackay Sean · CIK 0001875501 · SVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 760,174 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024 and March 21, 2025, which grants were originally reported on Form 3 and Form 4 filed with the U.S. Securities and Exchange Commission on September 3, 2024 and March 24, 2025, respectively. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 22:03 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 19,661 | $1.28 | $25,166.08 |
DisclosureSEC source: 0001193125-25-293841 · ownership.xml · nonDerivative · entry 1 Mackay Sean · CIK 0001875501 · SVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 779,835 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024 and March 21, 2025, which grants were originally reported on Form 3 and Form 4 filed with the U.S. Securities and Exchange Commission on September 3, 2024 and March 24, 2025, respectively. Read SEC document |
| August 20, 2025 Filed Aug 22, 2025 21:45 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 19,661 | $1.27 | $24,969.47 |
DisclosureSEC source: 0001193125-25-186506 · ownership.xml · nonDerivative · entry 1 Mackay Sean · CIK 0001875501 · SVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 799,496 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024 and March 21, 2025, which grants were originally reported on Form 3 and Form 4 filed with the U.S. Securities and Exchange Commission on September 3, 2024 and March 24, 2025, respectively. Read SEC document |
| May 28, 2025 Filed May 30, 2025 21:52 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 23,919 | $1.09 | $26,071.71 |
DisclosureSEC source: 0000950170-25-079890 · ownership.xml · nonDerivative · entry 1 Mackay Sean · CIK 0001875501 · SVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 819,157 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on March 21, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 24, 2025. Read SEC document |
| May 23, 2025 Filed May 28, 2025 21:52 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | SaleCommon Stock | 13,217 | $0.94 | $12,437.20 |
DisclosureSEC source: 0000950170-25-078463 · ownership.xml · nonDerivative · entry 1 Mackay Sean · CIK 0001875501 · SVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 843,076 F1 · shares: The shares were sold to satisfy the tax obligations that arose upon the vesting of restricted stock units granted to the reporting person on March 21, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission ("SEC") on March 24, 2025. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $0.92 to $0.9748 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 22, 2025 Filed May 23, 2025 22:13 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | SaleCommon Stock | 12,536 | $1.00 | $12,561.07 |
DisclosureSEC source: 0000950170-25-077191 · ownership.xml · nonDerivative · entry 2 Mackay Sean · CIK 0001875501 · SVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 856,293 F1 · shares: The shares were sold to satisfy the tax obligations that arose upon the vesting of restricted stock units granted to the reporting person on March 21, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission ("SEC") on March 24, 2025. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $0.9403 to $1.03 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 21, 2025 Filed May 23, 2025 22:13 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | SaleCommon Stock | 12,838 | $1.03 | $13,223.14 |
DisclosureSEC source: 0000950170-25-077191 · ownership.xml · nonDerivative · entry 1 Mackay Sean · CIK 0001875501 · SVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 868,829 F1 · shares: The shares were sold to satisfy the tax obligations that arose upon the vesting of restricted stock units granted to the reporting person on March 21, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission ("SEC") on March 24, 2025. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $1.015 to $1.05 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Read SEC document |
| March 21, 2025 Filed Mar 24, 2025 22:37 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 422,500 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0000950170-25-044011 · ownership.xml · derivative · entry 2 Mackay Sean · CIK 0001875501 · SVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 422,500 Underlying: Common Stock · 422,500 shares Expires 2035-03-21 F2 · derivative.exercise_date: The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2025, with the remaining shares vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| March 21, 2025 Filed Mar 24, 2025 22:37 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 281,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-044011 · ownership.xml · nonDerivative · entry 1 Mackay Sean · CIK 0001875501 · SVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 881,667 F1 · shares: Represents restricted stock units ("RSUs") that vest over four years, with 1/16th of the RSUs vesting on May 20, 2025 and the remaining RSUs vesting in equally quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:47 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 296,100 | Not disclosed Strike: $3.43 | Not disclosed |
DisclosureSEC source: 0001062993-23-007401 · form4.xml · derivative · entry 15 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 296,100 shares Expires 2032-03-31 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F16 · derivative.exercise_date: Vests 25% on March 31, 2023 and thereafter in 36 equal monthly installments. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:47 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 744,000 | Not disclosed Strike: $4.81 | Not disclosed |
DisclosureSEC source: 0001062993-23-007401 · form4.xml · derivative · entry 14 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 744,000 shares Expires 2031-06-07 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F15 · derivative.exercise_date: Vested 25% on June 8, 2020 and thereafter in 36 equal monthly installments. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:47 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 680,000 | Not disclosed Strike: $1.03 | Not disclosed |
DisclosureSEC source: 0001062993-23-007401 · form4.xml · derivative · entry 13 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 680,000 shares Expires 2030-04-18 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F14 · derivative.exercise_date: Vested in full as of December 15, 2020. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:47 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 96,000 | Not disclosed Strike: $0.96 | Not disclosed |
DisclosureSEC source: 0001062993-23-007401 · form4.xml · derivative · entry 12 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,000 shares Expires 2028-12-13 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F13 · derivative.exercise_date: Vested 25% on December 5, 2019 and thereafter in 36 equal monthly installments. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:47 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 40,000 | Not disclosed Strike: $0.73 | Not disclosed |
DisclosureSEC source: 0001062993-23-007401 · form4.xml · derivative · entry 11 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2028-09-26 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F12 · derivative.exercise_date: Vested 25% on September 27, 2019 and thereafter in 36 equal monthly installments. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:47 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 52,000 | Not disclosed Strike: $0.73 | Not disclosed |
DisclosureSEC source: 0001062993-23-007401 · form4.xml · derivative · entry 10 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,000 shares Expires 2028-06-28 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F11 · derivative.exercise_date: Vested 25% on June 29, 2019 and thereafter in 36 equal monthly installments. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:47 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 48,000 | Not disclosed Strike: $0.73 | Not disclosed |
DisclosureSEC source: 0001062993-23-007401 · form4.xml · derivative · entry 9 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,000 shares Expires 2028-02-11 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F10 · derivative.exercise_date: Vested 25% on August 1, 2018 and thereafter in 36 equal monthly installments. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:47 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 24,000 | Not disclosed Strike: $0.73 | Not disclosed |
DisclosureSEC source: 0001062993-23-007401 · form4.xml · derivative · entry 8 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2028-01-15 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F9 · derivative.exercise_date: Vested 25% on January 16, 2019 and thereafter in 36 equal monthly installments. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:47 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 112,000 | Not disclosed Strike: $0.73 | Not disclosed |
DisclosureSEC source: 0001062993-23-007401 · form4.xml · derivative · entry 7 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 112,000 shares Expires 2027-10-04 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F8 · derivative.exercise_date: Vested 25% on October 5, 2018 and thereafter in 36 equal monthly installments. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:47 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 14,000 | Not disclosed Strike: $0.73 | Not disclosed |
DisclosureSEC source: 0001062993-23-007401 · form4.xml · derivative · entry 6 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2027-10-04 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F7 · derivative.exercise_date: Vests 25% one year after achievement of sale target and thereafter in 36 equal monthly installments. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:47 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 14,000 | Not disclosed Strike: $0.73 | Not disclosed |
DisclosureSEC source: 0001062993-23-007401 · form4.xml · derivative · entry 5 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2027-10-04 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F6 · derivative.exercise_date: Vested 25% on December 26, 2019 upon achievement of performance target and thereafter in 36 equal monthly installments. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:47 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 52,000 | Not disclosed Strike: $0.44 | Not disclosed |
DisclosureSEC source: 0001062993-23-007401 · form4.xml · derivative · entry 4 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,000 shares Expires 2026-10-19 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F5 · derivative.exercise_date: Vested 25% on October 20, 2017 and thereafter in 36 equal monthly installments. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:47 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 19,000 | Not disclosed Strike: $0.28 | Not disclosed |
DisclosureSEC source: 0001062993-23-007401 · form4.xml · derivative · entry 3 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,000 shares Expires 2025-10-31 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F4 · derivative.exercise_date: Vested 25% on May 25, 2017 and thereafter in 36 equal monthly installments. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:47 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 834 | Not disclosed Strike: $0.28 | Not disclosed |
DisclosureSEC source: 0001062993-23-007401 · form4.xml · derivative · entry 2 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 834 shares Expires 2025-10-31 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option (whether vested or unvested) reported in this Form 4 (a) if the per-share exercise price was equal to or greater than the average closing trading price for a share of IsoPlexis Common Stock rounded to the nearest one-tenth of a cent, as reported on The Nasdaq Stock Market LLC for the five most recent trading days ending on and including the third business day prior to March 20, 2023 (the Company Trading Price), was canceled for no consideration and (b) if the per-share exercise price was less than the Company Trading Price, was converted into a Berkeley Lights stock option of approximately equivalent value and generally on the same terms and conditions. F3 · derivative.exercise_date: Vested 25% on August 31, 2019 and thereafter in 36 equal monthly installments. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:47 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerCommon Stock | 914,366 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-007401 · form4.xml · nonDerivative · entry 1 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On March 21, 2023, pursuant to the Agreement and Plan of Merger, dated as of December 21, 2022 (the Merger Agreement), by and among IsoPlexis Corporation, a Delaware corporation (IsoPlexis), Berkeley Lights, Inc., a Delaware corporation (Berkeley Lights), and Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Berkeley Lights, each share of common stock, par value $0.001, of IsoPlexis (IsoPlexis Common Stock) reported in this Form 4 was converted into the right to receive 0.6120 fully paid and nonassessable shares of common stock, par value $0.00005, of Berkeley Lights (Berkeley Lights Common Stock), together with cash in lieu of fractional shares of Berkeley Lights Common Stock, if any, and any unpaid dividends or other distributions. Read SEC document |
| August 25, 2022 Filed Aug 29, 2022 15:08 UTC | IsoPlexis Corp ISO · Entity 115290 | PurchaseCommon Stock | 15,000 | $1.99 | $29,850.00 |
DisclosureSEC source: 0001062993-22-018820 · form4.xml · nonDerivative · entry 1 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 914,366 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.91 to $2.15, inclusive. The reporting person undertakes to provide the issuer, any security holder, or the staff of the SEC, upon request, full information with respect to the foregoing. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 14:21 UTC | IsoPlexis Corp ISO · Entity 115290 | Exercise / conversionStock Option · Derivative | 61,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001062993-22-018546 · form4.xml · derivative · entry 4 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 61,000 shares Expires 2025-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options were subject to four-year vesting schedule with 25% vested on May 25, 2017 and the remainder vested in 36 equal monthly installments thereafter. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 14:21 UTC | IsoPlexis Corp ISO · Entity 115290 | Exercise / conversionStock Option · Derivative | 39,166 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001062993-22-018546 · form4.xml · derivative · entry 3 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 834 Underlying: Common Stock · 39,166 shares Expires 2025-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options subject to four-year vesting schedule with 25% vested on August 31, 2019 and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 14:21 UTC | IsoPlexis Corp ISO · Entity 115290 | Exercise / conversionCommon Stock | 61,000 | $0.28 | $17,006.80 |
DisclosureSEC source: 0001062993-22-018546 · form4.xml · nonDerivative · entry 2 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 899,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 14:21 UTC | IsoPlexis Corp ISO · Entity 115290 | Exercise / conversionCommon Stock | 39,166 | $0.28 | $10,919.48 |
DisclosureSEC source: 0001062993-22-018546 · form4.xml · nonDerivative · entry 1 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 838,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 15:09 UTC | IsoPlexis Corp ISO · Entity 115290 | GrantStock Option · Derivative | 296,100 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001062993-22-009306 · form4.xml · derivative · entry 1 Mackay Sean · CIK 0001875501 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,100 Underlying: Common Stock · 296,100 shares Expires 2032-03-31 F1 · derivative.exercise_date: Vests 25% on first anniversary of grant date and thereafter in 36 equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.